# Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)

> **NCT03656926** · PHASE3 · COMPLETED · sponsor: **Zambon SpA** · enrollment: 169 (actual)

## Conditions studied

- Bronchiolitis Obliterans
- Chronic Rejection of Lung Transplant
- Lung Transplant Rejection
- Lung Transplant; Complications
- Lung Transplant Failure and Rejection
- Chronic Lung Allograft Dysfunction

## Interventions

- **DRUG:** Liposomal Cyclosporine A
- **DRUG:** Standard of Care

## Key facts

- **NCT ID:** NCT03656926
- **Lead sponsor:** Zambon SpA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-26
- **Primary completion:** 2024-03-12
- **Final completion:** 2024-03-12
- **Target enrollment:** 169 (ACTUAL)
- **Last updated:** 2026-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03656926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03656926, "Efficacy + Safety of Liposome Cyclosporine A to Treat Bronchiolitis Obliterans Post Double Lung Transplant (BOSTON-2)". Retrieved via AI Analytics 2026-08-22 from https://api.ai-analytics.org/clinical/NCT03656926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*